OraSure Technologies Inc. (NASDAQ: OSUR) is a globally-recognized leader in the development, manufacture, and distribution of point-of-care diagnostic tests, molecular collection systems, and other technologies designed to detect and diagnose critical medical conditions. With its operational headquarters in Bethlehem, Pennsylvania, OraSure Technologies, or simply OraSure, has been pioneering progress in the global health industry for over 30 years.
Founded in 1987, OraSure Technologies originally started as SolarCare Technologies Corporation focused on the pharmaceutical industry. The company later rebranded and expanded its scope to cover medical device production, becoming a trailblazer in oral fluid technology.
Currently, OraSure's expansive portfolio of products targets various health-related issues, including HIV, Ebola, and Hepatitis C. The company gained global attention with its OraQuick ADVANCED® Rapid HIV-1/2 Antibody Test, the first FDA-approved oral fluid rapid test for HIV-1/2. It also manufactures the acclaimed OraQuick®Ebola Rapid Antigen Test and the OraQuick®HCV test.
One of OraSure's recent achievements is developing a molecular collection systems marketed under the Oragene® brand. These DNA and RNA collection systems were designed to maximize the precision and reliability of genetic testing.
More recently, in light of the global COVID-19 pandemic, OraSure has also directed its expertise towards contributing to coronavirus detection and control. It has received grant funding from the Biomedical Advanced Research and Development Authority (BARDA) to work toward the development of an in-home self-test for the novel coronavirus.
OraSure's dedication to healthcare and innovation has earned it a reputation of reliability and trust among clinicians, patients, and consumers globally. The company is dedicated to making testing simple, accessible, and reliable, and its products are sold in over 60 countries worldwide.
The commitment to enhancing global health is not only reflected in OraSure's product portfolio but also in its business operations. The company is committed to protecting and fostering human rights, minimizing its impact on the environment, and supporting the communities where it does business. OraSure Technologies’ mission and impact stretch far beyond its ongoing innovations in diagnostic testing, mimicking its dedication to contributing positively towards global healthcare.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Orasure Technologies has joined the World Coalition on Sickle Cell Disease, an international public-private partnership aimed at improving care for individuals affected by sickle cell disease globally. The company will contribute its expertise in diagnostics, particularly point-of-care tests, to help strengthen the connection between diagnosis and treatment. This collaboration seeks to facilitate earlier and more accurate diagnoses, especially in regions with limited medical access, and to ensure clear pathways to appropriate care and ongoing treatment.
OraSure Technologies announced a delay in achieving operational cash flow break-even status until the second half of 2027, citing shifting growth opportunities. Despite this, the Bethlehem-based medtech company reported revenue growth in its third quarter 2026 financial results and is focusing on expanding its HIV and Ebola testing products globally, particularly in Africa. The company's stock was down slightly after the announcement but remains up over 43% year-to-date.
OraSure Technologies reported a 14% year-over-year revenue increase to $30.9 million in Q3 2026, driven by growth in diagnostic products and strategic initiatives like local manufacturing in Africa for HIV and Ebola diagnostics. The company secured FDA Emergency Use Authorization for its OraQuick Ebola 2.0 Rapid Antigen Test and anticipates full-year 2026 revenue growth of 3.8% to 5.6%, expecting accelerated growth in 2027 while aiming for cash flow from operations break-even in the second half of 2027.
The fair value estimate for OraSure Technologies (OSUR) has increased from US$4.00 to US$5.50 per share, driven by renewed analyst discussion regarding stabilizing HIV and HCV testing trends and a potential inflection point in its core business. Craig Hallum initiated coverage with a Buy rating and a US$7 price target, citing potential mid-teens revenue growth after 12 quarters of declines. The report also highlights risks related to execution and funding, as the bullish thesis depends on a successful transition to sustained growth.
Analysts have raised their fair value estimate for OraSure Technologies (OSUR) from $4.00 to $5.50, driven by expectations of improved revenue trends, stabilized funding for HIV and HCV testing, and a higher future P/E multiple. Bullish views highlight the recent quarter as a potential inflection point for the core business, projecting mid-teens revenue growth after a period of declines. Bearish concerns include the company's history of revenue declines and execution risks, as well as sensitivity to public health budget shifts.
OraSure Technologies (OSUR) is scheduled to report its Q3 2026 earnings after market close on Monday, November 9th, with analysts forecasting a loss of $0.18 per share and revenue of approximately $31 million. The stock opened at $3.94, with a market capitalization of about $271.7 million, and currently holds a consensus "Hold" rating from analysts. Recent analyst actions include upgrades from "sell" to "hold" by Wall Street Zen and Zacks Research, and a "strong-buy" rating from Craig Hallum.
OraSure Technologies (NASDAQ:OSUR) saw its stock price climb above its 200-day moving average, reaching $4.18 before settling at $4.13. Despite this technical breakout, analyst sentiment remains cautious, with a consensus "Reduce" rating and a $3.00 target price. Institutional investors and hedge funds hold a significant 93.5% of the company's shares.